Law Firm of Wohl & Fruchter LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
NEW YORK--(BUSINESS WIRE)--The law firm of Wohl & Fruchter LLP announces that it has commenced an investigation into possible violations of federal securities laws by officers and directors of Questcor Pharmaceuticals, Inc. (Questcor) (Nasdaq: QCOR).
Questcor derives substantially all of its revenue from the sale of Repository Corticotropin Injection, also known as HP Acthar Gel (Acthar).
On September 14, 2012, Aetna, one of the largest private insurance providers in the United States, issued a Clinical Policy Bulletin concluding that based on its review of relevant medical studies, Acthar was “not medically necessary” for several conditions for which it has been prescribed, and that as a result, Aetna would cease coverage of Acthar for those conditions.
Wohl & Fruchter’s investigation concerns whether officers and directors of Questor violated federal securities laws by misstating or failing to disclose relevant information relating to Acthar, including its status as a drug approved for reimbursement with Aetna and other third party payers.
Persons with relevant information, and Questcor shareholders with questions about this investigation, are invited to contact our Firm by calling 866.582.8140.
Additional information is available on our website at: http://www.wohlfruchter.com/cases/qcor.
About Wohl & Fruchter
Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
This release may be deemed to constitute attorney advertising.
Wohl & Fruchter LLP
J. Elazar Fruchter (email@example.com)
845-425-4658 or Toll Free 866-582-8140
Posted: September 2012